Arrowhead Pharmaceuticals (ARWR) Revenue & Revenue Breakdown
Arrowhead Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$240.74M
Arrowhead Pharmaceuticals Revenue by Period
Arrowhead Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $240.74M | -1.03% |
| 2022-09-30 | $243.23M | 75.89% |
| 2021-09-30 | $138.29M | 57.16% |
| 2020-09-30 | $87.99M | -47.87% |
| 2019-09-30 | $168.80M | 945.67% |
| 2018-09-30 | $16.14M | -48.60% |
| 2017-09-30 | $31.41M | 19736.49% |
| 2016-09-30 | $158.33K | -58.55% |
| 2015-09-30 | $382.00K | 118.29% |
| 2014-09-30 | $175.00K | -39.71% |
| 2013-09-30 | $290.27K | 97.63% |
| 2012-09-30 | $146.88K | -50.40% |
| 2011-09-30 | $296.14K | -52.24% |
| 2010-09-30 | $620.10K | -83.57% |
| 2009-09-30 | $3.77M | 189.53% |
| 2008-09-30 | $1.30M | 7.88% |
| 2007-09-30 | $1.21M | 102.87% |
| 2006-09-30 | $595.46K | 0.81% |
| 2005-09-30 | $590.68K | 200.90% |
| 2004-09-30 | $196.31K | 100.00% |
| 2003-09-30 | - | -100.00% |
| 2002-09-30 | $2.27K | -75.67% |
| 2001-09-30 | $9.31K | -62.57% |
| 2000-09-30 | $24.88K | -32.76% |
| 1999-09-30 | $37.00K | -38.72% |
| 1998-09-30 | $60.38K | -21.17% |
| 1997-09-30 | $76.59K | - |
Arrowhead Pharmaceuticals generated $240.74M in revenue during NA 2023, up -1.03% compared to the previous quarter, and up 1491.33% compared to the same period a year ago.
Arrowhead Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $3.55M | -77.94% |
| 2023-09-30 | $16.10M | 1.72% |
| 2023-06-30 | $15.82M | -89.18% |
| 2023-03-31 | $146.27M | 133.86% |
| 2022-12-31 | $62.55M | 98.09% |
| 2022-09-30 | $31.57M | -2.58% |
| 2022-06-30 | $32.41M | -78.65% |
| 2022-03-31 | $151.81M | 453.25% |
| 2021-12-31 | $27.44M | -28.33% |
| 2021-09-30 | $38.28M | -16.58% |
| 2021-06-30 | $45.89M | 39.86% |
| 2021-03-31 | $32.81M | 54.02% |
| 2020-12-31 | $21.30M | 179.10% |
| 2020-09-30 | $7.63M | -72.12% |
| 2020-06-30 | $27.38M | 16.35% |
| 2020-03-31 | $23.53M | -20.12% |
| 2019-12-31 | $29.45M | -31.96% |
| 2019-09-30 | $43.29M | 1.40% |
| 2019-06-30 | $42.70M | -11.32% |
| 2019-03-31 | $48.15M | 38.92% |
| 2018-12-31 | $34.66M | 207.93% |
| 2018-09-30 | $11.26M | 1447.34% |
| 2018-06-30 | $727.38K | 11.88% |
| 2018-03-31 | $650.13K | -81.48% |
| 2017-12-31 | $3.51M | -59.72% |
| 2017-09-30 | $8.71M | -6.73% |
| 2017-06-30 | $9.34M | 3.97% |
| 2017-03-31 | $8.99M | 105.84% |
| 2016-12-31 | $4.37M | 13869.59% |
| 2016-09-30 | $31.25K | -21.05% |
| 2016-06-30 | $39.58K | -9.52% |
| 2016-03-31 | $43.75K | - |
| 2015-12-31 | $43.75K | - |
| 2015-09-30 | $43.75K | -64.65% |
| 2015-06-30 | $123.75K | 182.86% |
| 2015-03-31 | $43.75K | -74.38% |
| 2014-12-31 | $170.75K | 290.29% |
| 2014-09-30 | $43.75K | - |
| 2014-06-30 | $43.75K | - |
| 2014-03-31 | $43.75K | - |
| 2013-12-31 | $43.75K | - |
| 2013-09-30 | $43.75K | - |
| 2013-06-30 | $43.75K | - |
| 2013-03-31 | $43.75K | -72.49% |
| 2012-12-31 | $159.02K | 263.47% |
| 2012-09-30 | $43.75K | -8.70% |
| 2012-06-30 | $47.92K | 53.33% |
| 2012-03-31 | $31.25K | 30.44% |
| 2011-12-31 | $23.96K | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-03-31 | $296.14K | -94.07% |
| 2010-12-31 | $4.99M | 2664.32% |
| 2010-09-30 | $180.69K | 34.86% |
| 2010-06-30 | $133.99K | -14.84% |
| 2010-03-31 | $157.35K | 6.27% |
| 2009-12-31 | $148.07K | -26.91% |
| 2009-09-30 | $202.58K | -92.31% |
| 2009-06-30 | $2.63M | 1017.42% |
| 2009-03-31 | $235.65K | -66.42% |
| 2008-12-31 | $701.72K | -1273.49% |
| 2008-09-30 | $-59.80K | -125.41% |
| 2008-06-30 | $235.37K | -67.75% |
| 2008-03-31 | $729.77K | - |
Arrowhead Pharmaceuticals generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Arrowhead Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| IONS | Ionis Pharmaceuticals | $787.65M | $225.00M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| WVE | Wave Life Sciences | $113.31M | $19.69M |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ANNX | Annexon | - | - |
| NLTX | Neurogene | - | - |
| TERN | Terns Pharmaceuticals | - | - |
ARWR Revenue FAQ
What is Arrowhead Pharmaceuticals’s yearly revenue?
Arrowhead Pharmaceuticals's yearly revenue for 2023 was $240.74M, representing a decrease of -1.03% compared to 2022. The company's yearly revenue for 2022 was $243.23M, representing an increase of 75.89% compared to 2021. ARWR's yearly revenue for 2021 was $138.29M, representing an increase of 57.16% compared to 2020.
What is Arrowhead Pharmaceuticals’s quarterly revenue?
Arrowhead Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.55M, a -77.94% decrease from the previous quarter (Q4 2023), and a -94.32% decrease year-over-year (Q1 2023). ARWR's quarterly revenue for Q4 2023 was $16.1M, a 1.72% increase from the previous quarter (Q3 2023), and a -49.02% decrease year-over-year (Q4 2022).
What is Arrowhead Pharmaceuticals’s revenue growth rate?
Arrowhead Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 74.08%, and for the last 5 years (2019-2023) was 42.62%.